Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v13-FR | Version v10-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2020-03-04 | 2020-02-12 |
| Drug Identification Number | 02341689 | 02341689 |
| Brand name | GD-DICLOFENAC/MISOPROSTOL 50 | GD-DICLOFENAC/MISOPROSTOL 50 |
| Common or Proper name | GD-DICLOFENAC/MISOPROSTOL 50 | GD-DICLOFENAC/MISOPROSTOL 50 |
| Company Name | GENMED A DIVISION OF PFIZER CANADA ULC | GENMED A DIVISION OF PFIZER CANADA ULC |
| Ingredients | MISOPROSTOL DICLOFENAC SODIUM | MISOPROSTOL DICLOFENAC SODIUM |
| Strength(s) | 200MCG 50MG | 200MCG 50MG |
| Dosage form(s) | TABLET (DELAYED-RELEASE) | TABLET (DELAYED-RELEASE) |
| Route of administration | ORAL | ORAL |
| Packaging size | 250's | 250's |
| ATC code | M01AB | M01AB |
| ATC description | ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS | ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2019-11-22 | 2019-11-22 |
| Estimated end date | 2020-03-04 | 2020-03-04 |
| Actual end date | 2020-03-03 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Limited inventory available and on preventative allocation until approx March 4, 2020. Other presentation available: Arthrotec 50mg | Limited inventory available and on preventative allocation until approx March 4, 2020. Other presentation available: Arthrotec 50mg |
| Health Canada comments |